CB
CBUS.O
—
NASDAQ
Advanced Medical Equipment & Technology
Cibus Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
150,1M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-2 680,1 %
ROE
-582,2 %
Net margin
-3 492,3 %
Debt / equity
10,79
Beta
—
52w range
—
Volume
993
Day range
$1,45–$1,51
Prev close
$1,43
Open
$1,46
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Cibus Inc is a biotechnology company focused on developing and commercializing advanced medical equipment and technology, primarily in the healthcare services and equipment sector.
Business. Cibus Inc (CBUS.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm generates revenue through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Cibus is listed on the NASDAQ stock exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY3 analysts
2 buy1 hold0 sell
Avg 12m price target14,67
Analyst recommendations
3 analysts · consensus BuyBuy2
Hold1
Sell0
12-month price target
14,67
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
3 analysts · indicative
Ownership→
FMR LLC
largest disclosed fund holder
Profitability→
-582,2 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to CBUS.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Cibus Inc (CBUS.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm generates revenue through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Cibus is listed on the NASDAQ stock exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not provided in the available data.
Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
AI synthesis
GENERATEDCibus Inc has a market capitalization of $114.42 million and a price-to-book ratio of 5.24, indicating that the market is valuing the company at a premium to its book value. The company's liquidity position is weak, with a current ratio of 0.72 and negative free cash flow of -$126.96 million. The company's cash and equivalents of $9.92 million are significantly lower than its long-term debt of $235.45 million, resulting in a debt-to-equity ratio of 10.79.
Profitability metrics are deeply negative, with a return on equity of -5.82% and a return on assets of -0.42%. The company reported a net loss of $127.09 million and an operating loss of $97.53 million in the latest period. These figures are well below the industry median for profitability metrics, indicating significant underperformance relative to peers.
The company's revenue of $3.64 million is highly concentrated, with no disclosed segment or geographic breakdown. This lack of diversification increases exposure to market-specific risks. The absence of segment data also limits the ability to assess the performance of individual product lines or geographic regions.
Looking ahead, the company is expected to continue facing financial challenges. The current fiscal year is projected to see a continuation of losses, with no clear path to profitability in the near term. The company's capital expenditures of -$578,000 are minimal, suggesting limited investment in growth initiatives.
The company's risk profile is elevated, with a medium liquidity risk and a key flag indicating that net cash is negative after subtracting total debt. The dilution risk is currently low, but the company's high debt load and negative cash flow could necessitate future equity raises, which would increase dilution risk. The company has not issued any recent equity, and there are no immediate signs of dilution pressure.
Recent filings and transcripts indicate that the company is in a development phase, with a focus on research and development in the biotechnology space. However, there are no recent material events or earnings calls that suggest a near-term catalyst for value creation. The company's stock is currently trading at a significant discount to analyst price targets, with a mean target of $14.67 and a median target of $16.00.
Key takeaways
- Cibus Inc is trading at a premium to book value despite significant losses and negative cash flow.
- The company's liquidity position is weak, with a current ratio of 0.72 and a debt-to-equity ratio of 10.79.
- Profitability metrics are deeply negative, with a return on equity of -5.82% and a return on assets of -0.42%.
- The company's revenue is highly concentrated, with no disclosed segment or geographic breakdown.
- Analysts have set a wide range of price targets, from $3.00 to $25.00, with a mean of $14.67 and a median of $16.00.
- The company is in a development phase with no clear path to profitability in the near term.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$1,97
Market cap
$114.4M
Enterprise valueⓘ
$340.0M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
5.2x
P / Tangible bookⓘ
5.2x
Tangible book
$21.8M
Net cashⓘ
-$225.5M
Current ratioⓘ
0.7
Debt / equityⓘ
10.8
ROAⓘ
-41.7%
ROEⓘ
-5.8%
Cash conversionⓘ
40.0%
CapEx / revenueⓘ
-15.9%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships9 disclosed relationships · 3 types · extracted from filings & disclosures
Customers2
Partners1
THE PROCTER & GAMBLE COMPANYPG.TOPartner95%Source ↗
Subsidiaries6
EX21:30630dce51a8EX21:30630dce51a8Subsidiarie97%
EX21:6a3f8a91e951EX21:6a3f8a91e951Subsidiarie97%
EX21:7d2a0a6a1dfdEX21:7d2a0a6a1dfdSubsidiarie97%
EX21:80194df11c0fEX21:80194df11c0fSubsidiarie97%
EX21:8a7adb7b591eEX21:8a7adb7b591eSubsidiarie97%
EX21:fa46e5862e23EX21:fa46e5862e23Subsidiarie97%
Supply chain
Vendors → CBUS ↔ Partners → Customers · click any node to drill
3 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-07-04Peer comparison
Peer comparison8 peers · vs CBUS · multiples and returns
TM
TMO—
Thermo Fisher Scientific Inc
$574,03
214,1B USDP/E
29,4x
— vs self
Div yield
0,3 %
— vs self
ROE
12,9 %
+595,1 vs self
DH
DHR—
Danaher Corp
$197,50
140,1B USDP/E
38,2x
— vs self
Div yield
—
— vs self
ROE
6,9 %
+589,0 vs self
GE
GEHC—
GE HEALTHCARE TECHNOLOGIES INC.
$69,72
31,9B USDP/E
13,6x
— vs self
Div yield
0,2 %
— vs self
ROE
19,5 %
+601,7 vs self
PH
PHG—
PHG
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BS
BSX—
Boston Scientific Corp
$48,54
72,6B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
IS
ISRG—
INTUITIVE SURGICAL, INC.
$376,00
133,2B USDP/E
287,7x
— vs self
Div yield
—
— vs self
ROE
3,6 %
+585,8 vs self
A
A—
Agilent Technologies Inc
$139,80
39,6B USDP/E
29,0x
— vs self
Div yield
0,8 %
— vs self
ROE
19,3 %
+601,5 vs self
EW
EW—
Edwards Lifesciences Corp
$88,82
51,6B USDP/E
44,3x
— vs self
Div yield
—
— vs self
ROE
10,4 %
+592,6 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-1,15
Predicted surprise
+0,00
Beat probability
45 %
Analysts
3
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-10 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,15 |
| Revenue | —no estimate | —no estimate | 7,6M USD |
| Operating income | —no estimate | —no estimate | -49,6M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution3 analysts
Strong buy0
Buy2
Hold1
Sell0
Strong sell0
12-month price target$14,67 · Median $16,00
Low $3,00High $25,00
Operating income · consensus-49,6M USD
EPS surprise
−141,7 %
reported vs consensus · miss
Revenue surprise
−52,0 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$3,00
Mean$14,67
Median$16,00
High$25,00
Spot$1,97
+645.1 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin-2 680,1 %Bottom quartile
Net Margin-3 492,3 %Bottom quartile
ROE-582,2 %Bottom quartile
Capex / Rev-15,9 %Bottom quartile
D/E10,79Bottom quartile
Cash Conv0,40Bottom quartile
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 2 252 644 sh12 grants11 insiders
- CEO · Stock Option (Right-to-Buy) → Class A Common StockAcquired 1 047 620 @ $1,23grant · 2026-06-08
- Director · Stock Option (Right-to-Buy) → Class A Common StockAcquired 77 586 @ $1,39grant · 2026-06-02
- Director · Stock Option (Right-to-Buy) → Class A Common StockAcquired 77 586 @ $1,39grant · 2026-06-02
- Director · Stock Option (Right-to-Buy) → Class A Common StockAcquired 77 586 @ $1,39grant · 2026-06-02
- Director · Stock Option (Right-to-Buy) → Class A Common StockAcquired 77 586 @ $1,39grant · 2026-06-02
- Director · Stock Option (Right-to-Buy) → Class A Common StockAcquired 77 586 @ $1,39grant · 2026-06-02
- CAO, Gen Csl & Corp Secy · Stock Option (Right-to-Buy) → Class A Common StockAcquired 114 000 @ $1,50grant · 2026-04-24
- Interim CEO, Pres & COO · Stock Option (Right-to-Buy) → Class A Common StockAcquired 390 000 @ $1,50grant · 2026-04-24
- Chief Scientific Officer & EVP · Stock Option (Right-to-Buy) → Class A Common StockAcquired 114 000 @ $1,50grant · 2026-04-24
- CFO · Stock Option (Right-to-Buy) → Class A Common StockAcquired 114 000 @ $1,50grant · 2026-04-24
- Sr VP, Research · Stock Option (Right-to-Buy) → Class A Common StockAcquired 76 000 @ $1,50grant · 2026-04-24
- Director · Stock Option (Right-to-Buy) → Class A Common StockAcquired 9 094 @ $1,50grant · 2026-04-24
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
Source documents
- Cibus Inc Market data — financials · 2026-05-27
- Cibus Inc Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,00 %$23M
- Investment Managers · as of 2024-06-300,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$2M
- Investment Managers · as of 2024-12-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Mixed / flat0 buys · 0 sellsnet $09 insiders · last 365d
- CEO · Class A Common StockOther 894 309 · 2026-06-08
- Director · Class A Common StockOther 64 748 · 2026-06-02
- Director · Class A Common StockOther 64 748 · 2026-06-02
- Director · Class A Common StockOther 64 748 · 2026-06-02
- Sr VP, Research · Class A Common StockOther 38 000 · 2026-04-24
- CAO, Gen Csl & Corp Secy · Class A Common StockOther 57 000 · 2026-04-24
- CFO · Class A Common StockOther 57 000 · 2026-04-24
- Chief Scientific Officer & EVP · Class A Common StockOther 57 000 · 2026-04-24
- Interim CEO, Pres & COO · Class A Common StockOther 195 000 · 2026-04-24
- Sr VP, Research · Class A Common StockOther 1 763 @ $1,84$3K · 2026-03-30
- CLO, Gen Csl & Secy · Class A Common StockOther 3 695 @ $1,83$7K · 2026-03-30
- CFO · Class A Common StockOther 3 676 @ $1,87$7K · 2026-03-30
- Chief Scientific Officer & EVP · Class A Common StockOther 8 954 @ $1,82$16K · 2026-03-30
- Director, Interim CEO, Pres & COO · Class A Common StockOther 16 112 @ $1,85$30K · 2026-03-30
- CLO, Gen Csl & Secy · Class A Common StockOther 4 795 @ $2,98$14K · 2026-02-19
- Director · Class A Common StockOther 666 666 @ $1,50$1 000K · 2026-01-29
- CFO · Class A Common StockOther 1 496 @ $1,32$2K · 2025-11-11
- Sr VP, Research · Class A Common StockOther 1 834 @ $1,32$2K · 2025-11-11
- CLO, Gen Csl & Secy · Class A Common StockOther 3 519 @ $1,32$5K · 2025-11-11
Short positioning
3.5Mshares short-24.2% vs prior
4.7days to cover
38.6%short of daily vol
7.5Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
CBUS.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorCustomersPartnersSubsidiaries
Evidence & claims
From filings & derived data- Revenue (YoY) (2025-12-31 vs 2024-12-31): -14.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 62.3%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 12.97xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -31.2%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 49.4%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -76.3%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.72xDerived (calculated)
- Return on assets (FY 2025-12-31): -41.7%Derived (calculated)
- Return on equity (FY 2025-12-31): -582.2%Derived (calculated)
- Net margin (FY 2025-12-31): -3,492.3%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -20.2%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -12.9%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 12.3%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 12.8%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 74.3%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -28.5%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): -12.4%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 74.3%Derived (calculated)
- Current liabilities (annual): USD 16.86MSEC XBRL filing
- Operating cash flow (annual): USD -50.59MSEC XBRL filing
- Long-term debt (annual): USD 528KSEC XBRL filing
- Current assets (annual): USD 12.07MSEC XBRL filing
- Revenue (annual): USD 3.64MSEC XBRL filing
- Net income (annual): USD -127.08MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
2026-06-08 00:00 UTCINSIDER10 insider transactions — 2026-06 6 derivative
2026-06-08INSIDERWichner Craig transacted 894.3k sh Class A Common Stock — CEO
2026-06-08INSIDERWichner Craig acquired 1.05M sh Stock Option (Right-to-Buy) — CEO
2026-06-02INSIDERLehmann Jean-Pierre Jules transacted 64.7k sh Class A Common Stock — Director
2026-06-02INSIDERUrban Thomas transacted 64.7k sh Class A Common Stock — Director
2026-06-02INSIDERPrante Gerhard transacted 64.7k sh Class A Common Stock — Director
2026-06-02INSIDERBox Kimberly Ann acquired 77.6k sh Stock Option (Right-to-Buy) — Director
2026-06-02INSIDERWichner Craig acquired 77.6k sh Stock Option (Right-to-Buy) — Director
2026-06-02INSIDERFinn Mark Terrence acquired 77.6k sh Stock Option (Right-to-Buy) — Director
2026-06-02INSIDERMoretti August J acquired 77.6k sh Stock Option (Right-to-Buy) — Director
2026-06-02INSIDERRIGGS RORY B acquired 77.6k sh Stock Option (Right-to-Buy) — Director
2026-04-24 00:00 UTCINSIDER11 insider transactions — 2026-04 6 derivative
2026-04-24INSIDERSauer Noel transacted 38.0k sh Class A Common Stock — Sr VP, Research
2026-04-24INSIDERStokes Jason transacted 57.0k sh Class A Common Stock — CAO, Gen Csl & Corp Secy
2026-04-24INSIDERBroos Carlo transacted 57.0k sh Class A Common Stock — CFO
2026-04-24INSIDERGocal Gregory Francis William transacted 57.0k sh Class A Common Stock — Chief Scientific Officer & EVP
2026-04-24INSIDERBeetham Peter transacted 195.0k sh Class A Common Stock — Interim CEO, Pres & COO
2026-04-24INSIDERUrban Thomas acquired 9.1k sh Stock Option (Right-to-Buy) — Director
2026-04-24INSIDERSauer Noel acquired 76.0k sh Stock Option (Right-to-Buy) — Sr VP, Research
2026-04-24INSIDERStokes Jason acquired 114.0k sh Stock Option (Right-to-Buy) — CAO, Gen Csl & Corp Secy
2026-04-24INSIDERBroos Carlo acquired 114.0k sh Stock Option (Right-to-Buy) — CFO
2026-04-24INSIDERGocal Gregory Francis William acquired 114.0k sh Stock Option (Right-to-Buy) — Chief Scientific Officer & EVP
2026-04-24INSIDERBeetham Peter acquired 390.0k sh Stock Option (Right-to-Buy) — Interim CEO, Pres & COO
2026-03-30 00:00 UTCINSIDER5 insider transactions — 2026-03
2026-03-30INSIDERSauer Noel transacted 1.8k sh Class A Common Stock — Sr VP, Research ~$3k
2026-03-30INSIDERStokes Jason transacted 3.7k sh Class A Common Stock — CLO, Gen Csl & Secy ~$7k
2026-03-30INSIDERBroos Carlo transacted 3.7k sh Class A Common Stock — CFO ~$7k
2026-03-30INSIDERGocal Gregory Francis William transacted 9.0k sh Class A Common Stock — Chief Scientific Officer & EVP ~$16k
2026-03-30INSIDERBeetham Peter transacted 16.1k sh Class A Common Stock — Director, Interim CEO, Pres & COO ~$30k
Showing the 40 most recent of 54 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage